Şirket yükleniyor
Just reported
Q3 2026 results
From Opus Genetics's results release of 10 Kasım 2026; its quarterly report has since been filed.
Revenue
Actual
$1,1M
-%63 y/y
+%51 q/qGuided
—
No guide given
EPS, GAAP
Actual
-$0,46
Guided
—
No guide given
Operating income, GAAP
Actual
-$19,2M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Opus Genetics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47,5BA+
EXELExelixis, Inc.$17BA+
JAZZJazz Pharmaceuticals plc$15,4BA
HALOHalozyme Therapeutics, Inc.$11,5BA+
TECHBIO-Techne Corp$11,4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
BIIBBiogen Inc.28 Eki 2026BAGraded B, now A
Opus Genetics, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
